Trial Profile
A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Dec 2021
Price :
$35
*
At a glance
- Drugs DA 1241 (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Dong-A ST
- 29 Jun 2021 Results (n=24) assessing safety, tolerability, and pharmacokinetics from part 1 of a phase 1b multiple ascending dose study in healthy volunteers, presented at the 81st Annual Scientific Sessions of the American Diabetes Association
- 29 Jun 2021 Results (n=72) of Part 2 assessing the safety, tolerability and PK profiles of DA-1241, presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
- 08 Feb 2021 According to a Dong-A ST Media Release, data from this trial will be presented at the American Diabetes Association conference 2021.